Neural Therapeutics Inc. · CSE:NURL
Neural Therapeutics — Investor Presentation (November 2021)
28 slides from Neural Therapeutics's investor presentation, November 2021
Slide 1: Neural Therapeutics Inc. Corporate Presentation
Neural Therapeutics Inc. Corporate Presentation November 2021
Slide 2: Forward Looking Statements
Forward Looking Statements Forward-Looking Statement and Risk Factors By their very nature, forward-looking statements involve inherent risks and uncertainties, both This presentation is provided by Neural Therapeutics Inc. (the “Company”) and includes certain “forward- general and specific, and ris
Slide 3: Executive Overview
Executive Overview • Neural Therapeutics Inc. is an ethnobotanical drug-discovery/development company focused on developing products and conducting research with psychoactive plants. The first being San Pedro (Echinopsis pachanoi or Trichocereus pachanoi), a cactus containing mescaline. • We aim to
Slide 4: Market Stats - Pharmaceutical
Market Stats - Pharmaceutical We are targeting a potentially $70+ billion target market. Institutional Market Momentum ADHD: $29.6 Billion Anti-Addiction: $6.1 Billion Anxiety: $10.9 Billion Smoking Cessation: $23.4 Billion • Veterans of War & Heroic Hearts Project: are 2 examples of non- profits th
Slide 5: Market Stats - Nutraceutical
Market Stats - Nutraceutical We are targeting a potentially $175+ billion target market. Weight Loss Dietary ❖ Clinical Proof: Recently, cacti fiber was clinically proven to scavenge $24 Billion $140 Billion Supplements: Supplements: dietary fat and reduce obesity in separate studies. ❖ Benefits: Ca
Slide 6: San Pedro Derived Mescaline Today – North America
San Pedro Derived Mescaline Today – North America A trend to relax laws regarding psychedelics to reduce epidemic street drug trends and provide a pathway to therapeutics. Decriminalization Movements in States and Provinces San Pedro-Mescaline and Psychedelics in the US British Columbia: Nov 1, 2021
Slide 7: Targeted Milestones and Objectives
Targeted Milestones and Objectives Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 ➢ Complete seed financing; ➢ Finalize engagement of a ➢ Finalize SOP ➢ Target NHP/Dietary ➢ Target NHP/Dietary university research partner development and Supplement product Supplement product ➢ Finalize spin-off plans from o
Slide 8: Past Milestones
Past Milestones Review and Research and Development Initial literature review $1.5M Raised Acquisition by feedback collection Planning with Rangsit Company Formed and cactus species Nutritional High from 3rd parties University in Thailand identification Q1 2020 Q2 2020 Q3 - Q4 2020 CRO engaged for A
Slide 9: Pharmaceutical Market Strategy
Pharmaceutical Market Strategy The pharmaceutical strategy will focus on monetizing the mescaline containing portion of the cactus. ❖ Aim: To obtain insight into potential efficacy of the compounds that may be applied to the Pharmaceutical and Nutraceutical markets. Our goals are not dependent upon
Slide 10: Nutraceutical Market Strategy
Nutraceutical Market Strategy The nutraceutical strategy will focus on monetizing the non-mescaline portion of the cactus. Mescaline is not equally distributed throughout San Pedro. It resides mainly in the outer surfaces. Our focus will be to efficiently extract mescaline and other medically benefi
Slide 11: Neural Therapeutics Advantage
Neural Therapeutics Advantage We are undertaking a holistic approach to respect the traditional use of the plant. Used Throughout History: Mescaline has been used for nearly 6000 years and delivered through San Pedro. It is considered a relatively safe psychedelic. Safety: Mescaline requires larger
Slide 12: Why we are focusing on plant sourced mescaline
Why we are focusing on plant sourced mescaline The advantages of natural sourced materials, in particular the San Pedro cactus Mescaline is Safer ❖ We believe Mescaline is safer when compared to other psychedelics – Greater masses are required to achieve full effect . Reducing the chance of over-dos
Slide 13: R&D Targeted Near-Term Objectives – Common to Pharmaceutical and Nutraceutical
R&D Targeted Near-Term Objectives – Common to Pharmaceutical and Nutraceutical Our aim is to strategically identify and take advantage of an understudied area of the psychedelic market in key steps. Supply Chain: Identify a cGMP/CMC Supply Chain ensuring high quality starting materials a processes t
Slide 14: R&D Targeted Deliverables Objectives - Pharmaceutical
R&D Targeted Deliverables Objectives - Pharmaceutical Our aim is to strategically identify and take advantage of an understudied area of the psychedelic market in key steps. Step 1 – Firm-up Path to Market and Conduct Fundamental Research Studies: ❖ Dosage: Identify the optimal safe therapeutic dose
Slide 15: R&D Targeted Deliverables Objectives - Nutraceutical
R&D Targeted Deliverables Objectives - Nutraceutical Focus on extracting benefit from all parts of the cactus plant. ❖ Raw Material: The residual San Pedro solids and extracts separated from mescaline are the raw materials – determine the composition of the parts that have potential therapeutic bene
Slide 16: Legality of San Pedro Globally
Legality of San Pedro Globally Unlike Peyote, possession of the San Pedro cactus is legal in most parts of the world. Peru: sold freely and widely as an ornamental purposes. Religious, traditional and folklore use is permitted in some circumstances; mescaline is category IB General: controlled subst
Slide 17: Why focus on Peru?
Why focus on Peru? Peru offers easier and broader access to the San Pedro plant and other similar species. Supply Chain: ❖ San Pedro is a native, hardy, plant and readily grows in the Northern Peru areas. There is no shortage of materials. ❖ There is a great deal of variability of mescaline concentr
Slide 18: Proposed Leadership Team
Proposed Leadership Team Ian Campbell, MSc – Chief Executive Officer and Director – Mr. Campbell is an executive leader who has an international reputation for building effective teams, managing operations and product commercialization. He has managed multinational entities residing in the US, Canad
Slide 19: Proposed Scientific & Impact Advisory Committee
Proposed Scientific & Impact Advisory Committee Professor David Nutt – David Nutt is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Imperial College London. He was previously President of the, European Brain Council, British Association
Slide 20: Pro-Forma Capitalization and Budget
Pro-Forma Capitalization and Budget % Budget Item Amount Number % FD Basic 26,666,667 53% 40% R&D – Main $300,000 Common Shares Currently Issued and Outstanding 1 10,000,000 20% 15% R&D - Pharmaceutical $500,000 Seed Financing ($750,000 @ $0.075) 13,333,333 27% 20% R&D – Nutraceutical $250,000 Concu
Slide 21: Market Comparables
Market Comparables Mescaline is an emerging focus on pubcos; NT’s value proposition has compelling upside potential Company Name Ticker Mkt Cap ($MM) 1 • New York-based psychedelic medicine biotech company Small Pharma Inc. TSXV:DMT $152.5 that develops psychedelic-inspired medicines and therapies B
Slide 22: Contact Us
Contact Us Ian Campbell, CEO Neural Therapeutics Inc. C: 226-218-2255 E: icampbell@neuraltherapeutics.com 77 King Street West, Suite 2905 Toronto, ON M5K 1H1 22
Slide 23: Statutory Rights of Action
Statutory Rights of Action This presentation may be considered an offering memorandum (the “Offering Memorandum”) thereby granting the potential purchasers statutory rights and contractual rights of action. Securities legislation in certain of the provinces and territories of Canada provides purcha
Slide 24: Appendix: Sources – Market Statistics
Appendix: Sources – Market Statistics Pharmaceutical • ADHD: ADHD Therapeutics Market Size, Trends & Growth | 2021 to 2026 (marketdataforecast.com) • Anti-addiction: Addiction Treatment Market Size is Projected to Reach US$ 11 Billion by 2027 – The Market Publicist • Anxiety: Anxiety Disorders and D
Slide 25: Neural Therapeutics Philosophy
Neural Therapeutics Philosophy Why we are focusing on mescaline from natural sources, in particular the San Pedro cactus? Mescaline is Different Honoring Ethnobotanical Use ❖ Serotonin 2A (5-HT2A) receptor drug interaction is different for each ❖ Thousands of years of native experience is an invalua
Slide 26: History of Mescaline
History of Mescaline Mescaline has been widely used throughout our history. Mescaline is found in the fast- Dr. John Raleigh Briggs wrote German pharmacologist and physicist Failure of Mescaline to solve the growing San Pedro cactus and the about his experience after eating Arthur Heffter isolated t
Slide 27: About Psychedelic Cacti
About Psychedelic Cacti Native populations have used botanical medicines such as Peyote and San Pedro for millennia. Contains the highest concentration of Mescaline – Despite the lower mescaline around 3 to 6% of the dried weight. concentration at around 1 - 4.5%, the larger size of the San Pedro Ca
Slide 28: Mescaline vs. Other Psychedelics
Mescaline vs. Other Psychedelics Psychedelic Molecular Typical Duration of Potential Therapeutic Uses Onset of Effects Substance Structure Hallucination Dose Effects Addiction (e.g., alcohol), Anxiety LSD 0.05-0.2 mg 30-40 min 8-12h associated with terminal illness Addiction (tobacco, alcohol), Psil
Neural Therapeutics — Investor Presentation (November 2021) on 6ix